⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28076178 | 0.97 | — | — | |
| SCHEMBL841786 | 0.92 | — | — | |
| SCHEMBL1059967 | 0.79 | — | — | |
| SCHEMBL23141888 | 0.71 | — | — | |
| SCHEMBL8065 | 0.71 | — | — | |
| SCHEMBL3551064 | 0.67 | — | — | |
| SCHEMBL4200363 | 0.67 | — | — | |
| SCHEMBL10957942 | 0.67 | — | — | |
| SCHEMBL4417926 | 0.67 | — | — | |
| SCHEMBL8906864 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197711-A1 | Combination Therapy for Cancer Treatment | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-20 | — | — | US | claimed |
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-04-18 | — | — | US | claimed |
| EP-4313029-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | The Regents of The University of Michigan (US) | 2024-02-07 | — | — | EP | claimed |
| EP-4288416-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | The Regents Of The University Of Michigan (US) | 2023-12-13 | — | — | EP | claimed |
| US-20230098205-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-03-30 | — | — | US | claimed |
| US-20230097789-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2023-03-30 | — | — | US | claimed |
| EP-4114387-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | The Regents of The University of Michigan (US) | 2023-01-11 | — | — | EP | claimed |
| EP-4114386-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | The Regents of The University of Michigan (US) | 2023-01-11 | — | — | EP | claimed |
| WO-2022169834-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021178741-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-10 | — | — | WO | claimed |
| WO-2021178740-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-10 | — | — | WO | claimed |
| WO-2020132459-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-06-25 | — | — | WO | claimed |
| EP-3648753-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2020-05-13 | — | — | EP | claimed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | claimed |
| CN-109328059-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2019-02-12 | — | — | CN | claimed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | claimed |
| WO-2019010295-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2019-01-10 | — | — | WO | claimed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | claimed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | claimed |
| US-20240197711-A1 | Combination Therapy for Cancer Treatment | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-06-20 | — | — | US | disclosed |
| US-20240124419-A1 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-04-18 | — | — | US | disclosed |
| EP-4313029-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | The Regents of The University of Michigan (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4288416-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | The Regents Of The University Of Michigan (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230098205-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-03-30 | — | — | US | disclosed |
| US-20230097789-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4114387-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | The Regents of The University of Michigan (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4114386-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | The Regents of The University of Michigan (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022169834-A2 | SMALL MOLECULE INHIBITORS OF GRP78 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021178741-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178740-A1 | INHIBITORS OF EGFR, KRAS, BRAF, AND OTHER TARGETS AND USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-10 | — | — | WO | disclosed |
| CN-109328059-B | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020132459-A1 | QUINOLINYL-PYRAZINE-CARBOXAMIDE COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-3648753-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2020-05-13 | — | — | EP | disclosed |
| CN-111093645-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| CN-109328059-A | Selective inhibitors of clinically important mutants of EGFR tyrosine kinase | CS制药技术有限公司 | 2019-02-12 | — | — | CN | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| WO-2019010295-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2019-01-10 | — | — | WO | disclosed |
| EP-3399968-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmatech Limited (KY) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017120429-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS Pharmasciences, Inc. (US) | 2017-07-13 | — | — | WO | disclosed |